Questcor announces new neurology focus

As part of its new strategic direction, Questcor will initially focus its sales and marketing resources on promoting its multiple sclerosis treatment HP Acthar Gel (repository corticotropin injection) to neurologists. HP Acthar Gel is currently the company’s largest product in terms of sales, but has not been the focus of recent marketing efforts.

In addition, the company will pursue the licensing and acquisition of products which leverage its focused neurology efforts. Questcor also plans to begin building a development pipeline of new products that have the potential to address significant unmet medical needs in the CNS field, using both its own intellectual property and intellectual property licensed from other companies.

“These major strategic changes will allow us to become an integrated specialty pharmaceutical company, focused in a dynamic area of medicine which holds great opportunity for improving patient outcomes,” said James Fares, Questcor’s president and CEO. “Over the last few months, we have assembled a management team with a proven track record of success in developing and commercializing CNS products. We believe this will enable us to execute our new strategy.”